Wall Street analysts expect Edwards Lifesciences Corp (NYSE:EW) to report earnings per share (EPS) of $0.41 for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for Edwards Lifesciences’ earnings. The lowest EPS estimate is $0.30 and the highest is $0.51. Edwards Lifesciences reported earnings of $0.46 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 10.9%. The business is scheduled to report its next earnings report on Tuesday, July 28th.
On average, analysts expect that Edwards Lifesciences will report full-year earnings of $1.65 per share for the current financial year, with EPS estimates ranging from $1.58 to $1.75. For the next fiscal year, analysts expect that the business will post earnings of $2.16 per share, with EPS estimates ranging from $1.94 to $2.35. Zacks’ EPS averages are an average based on a survey of analysts that cover Edwards Lifesciences.
Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.50 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.07. The company had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Edwards Lifesciences had a return on equity of 31.83% and a net margin of 24.71%. Edwards Lifesciences’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.44 EPS.
EW traded up $0.36 during midday trading on Thursday, reaching $68.25. 34,110 shares of the company’s stock traded hands, compared to its average volume of 3,371,622. The firm has a fifty day moving average of $109.88 and a two-hundred day moving average of $82.02. The stock has a market capitalization of $41.60 billion, a price-to-earnings ratio of 38.94, a P/E/G ratio of 2.53 and a beta of 0.84. The company has a debt-to-equity ratio of 0.17, a current ratio of 3.36 and a quick ratio of 2.47. Edwards Lifesciences has a 52 week low of $51.51 and a 52 week high of $82.55.
In other Edwards Lifesciences news, VP Larry L. Wood sold 3,566 shares of the stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $180.84, for a total transaction of $644,875.44. Following the sale, the vice president now directly owns 121,102 shares in the company, valued at approximately $21,900,085.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,369 shares of the stock in a transaction on Friday, April 3rd. The shares were sold at an average price of $182.44, for a total value of $979,520.36. Following the sale, the vice president now owns 26,191 shares in the company, valued at $4,778,286.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 194,323 shares of company stock valued at $25,124,106. 1.48% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Princeton Global Asset Management LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $26,000. Procyon Private Wealth Partners LLC lifted its position in Edwards Lifesciences by 276.3% during the first quarter. Procyon Private Wealth Partners LLC now owns 143 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 105 shares in the last quarter. 1776 Wealth LLC lifted its position in Edwards Lifesciences by 97.6% during the first quarter. 1776 Wealth LLC now owns 162 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 80 shares in the last quarter. Balentine LLC purchased a new position in Edwards Lifesciences during the first quarter valued at $32,000. Finally, Trust Co. of Vermont lifted its position in Edwards Lifesciences by 65.4% during the first quarter. Trust Co. of Vermont now owns 253 shares of the medical research company’s stock valued at $48,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: Nikkei 225 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.